Potential role of plasma myeloperoxidase level: In predicting long-term outcome of acute myocardial infarction

Texas Heart Institute Journal

Volumn 39, Issue 4, 2012, Pages 500-506

  Kaya, Mehmet Gungor ^a   Yalcin, Ridvan ^b   Okyay, Kaan ^b   Poyraz, Fatih ^b   Bayraktar, Nilufer ^c   Pasaoglu, Hatice ^b   Boyaci, Bulent ^b   Cengel, Atiye ^b  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

Author keywords

Biological markers blood; C reactive protein; Coronary artery disease blood enzymology; Creatine kinase, MB form; Long term outcome; Major adverse cardiac event; Myocardial infarction, acute blood enzy mology; Peroxidase blood; Prospective studies; Survival analysis; Troponin T

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE MB; FIBRINOGEN; MYELOPEROXIDASE; TROPONIN T;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIAGNOSTIC KIT; DISEASE COURSE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; IMAGING SYSTEM; IMMUNOASSAY; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PLASMA; PROGNOSIS; PROSPECTIVE STUDY; REFERENCE VALUE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; ODDS RATIO; PATIENT READMISSION; PEROXIDASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TURKEY; UP-REGULATION; YOUNG ADULT;

EID: 84865856133     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92(3):657-71.
2. Arnhold J. Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Mosc) 2004;69(1):4-9.
3. Schmitt D, Shen Z, Zhang R, Colles SM, Wu W, Salomon RG, et al. Leukocytes utilize myeioperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. Biochemistry 1999;38(51):16904-15.
4. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94(1):437-44. (Pubitemid 24218123)
5. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke J W, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158(3):879-91. (Pubitemid 32221781)
6. Fu X, Kassim SY, Parks WC, Heinecke J W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276(44):41279-87.
7. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349(17):1595-604. (Pubitemid 37288567)
8. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007;99(10):1364-8. (Pubitemid 46686633)
9. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21(18):1502-13.
10. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) [published erratum appears in Circulation 2005;111(15):2013].
11. Circulation 2004;110(5):588-636.
12. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993:22(4 Suppl A):6A-13A. (Pubitemid 23285789)
13. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007;93(7):826-31. (Pubitemid 46998982)
14. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49(20):1993-2000. (Pubitemid 46734639)
15. Chang LT, Chua S, Sheu JJ, Wu CJ, Yeh KH, Yang CH, Yip HK. Level and prognostic value of serum myeloperoxidase in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 2009;73(4):726-31.
16. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001 ;286(17):2136-42. (Pubitemid 34041599)
17. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340(2):115-26. (Pubitemid 29054847)
18. Canale ML, Stroppa S, Caravelli P, Petronio AS, Mariotti R, Mariani M, et al. Admission C-reactive protein serum levels and survival in patients with acute myocardial infarction with persistent ST elevation. Coron Artery Dis 2006;17(8):693-8. (Pubitemid 44934701)
19. Yip HK, Hang CL, Fang CY, Hsieh YK, Yang CH, Hung WC, Wu CJ. Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest 2005; 127(3): 803-8.
20. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996;17(9):1345-9. (Pubitemid 26306662)
21. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mi-tamura H, Ogawa S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997;96(3):778-84. (Pubitemid 27329609)
22. Dibra A, Mehilli J, Schwaiger M, Schuhlen H, Bollwein H, Braun S, et al. Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. Eur Heart J 2003;24(12):1128-33. (Pubitemid 36723578)
23. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003:362(9380): 316-22. (Pubitemid 36936846)
24. Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next [published erratum appears in Circulation 2002;106(3):387]
25. Circulation 2002;105(20):2328-31.
26. Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Rifai N, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004;44(2):335-9. (Pubitemid 38950592)
27. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Her-litz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106(23):2913-8. (Pubitemid 35424741)
28. Nilsson L, Hallen J, Atar D, Jonasson L, Swahn E. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 2012;98(1):31-6.